[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lactation-suppressed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lactation-suppressed":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100585957","phase-2-a-reduced-dose-of-cabergoline-for-lactation-inhibition-after-second-trimester-abortion-or-pregnancy-loss-100585957",false,"NCT06909123","A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss","LISTA3","Inclusion Criteria:\n\n* Pregnant people, ages 18 years or older\n* Intrauterine pregnancy between 16\u002F0-25\u002F6 weeks of gestation age (by ultrasound dating performed prior to or same day of enrollment visit)\n* Consented for an induced, elective abortion or undergoing management of fetal demise\n* English or Spanish speaking\n* Able to consent for a research study, literate in English or Spanish\n* Willing to comply with study procedures and follow-up\n* Access to smart phone throughout study\n\nExclusion Criteria:\n\n* Prior mastectomy (breast reduction or chest masculinization surgery acceptable)\n* Currently breastfeeding\n* Currently receiving dopamine agonist or antagonist therapy for other indication leg syndrome)\n* Contraindication to cabergoline (as per package insert)\n* Uncontrolled hypertension - defined as baseline BP \\> 160\u002F110, or chronic hypertension requiring more than one baseline medication, or current pregnancy-induced hypertension spectrum disorders (gestational hypertension, preeclampsia, eclampsia)\n* History of cardiac valvular disorders or valvular repair\n* History of pulmonary, pericardial, or retroperitoneal fibrotic disorders","FEMALE","18 Years","55 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergoline has been previously demonstrated to prevent breast symptoms for these patients. This study seeks to determine if investigators can more precisely manage these patients with a reduced dose appropriate for the physiology of the second trimester, thereby reducing the medication cost and reducing or eliminating the uncomfortable medication side effects.",[27],"Lactation Suppressed","NOT_YET_RECRUITING","2025-12-05",{"date":31,"type":32},"2025-12-12","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2027-07",{"name":38,"class":39},"Stanford University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100525537","phase-4-pharmacological-inhibition-of-lactation-after-16-to-20-week-abortion-100525537","NCT06123026","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial","Inclusion Criteria:\n\n* pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises\n* ages 18 to 50\n* con provide informed consent in English\n\nExclusion Criteria:\n\n* Age under 18 or above 50\n* gestational ages before 16 weeks 0 days or after 20 weeks 0 days\n* unable to provide written consent in English\n* hypertensive disorder\n* uncontrolled hypertension or known hypersensitivity to ergot derivatives\n* History of cardiac valvular disorders\n* history of pulmonary fibrosis\n* documented bipolar schizophrenia\n* documented allergy to medication, including lactose intolerance (placebo pill involves lactose)",true,"50 Years",{"count":50,"type":21},200,[52],"PHASE4","The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called \"cabergoline\" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.",[27,55],"Second Trimester Abortion","RECRUITING","2024-05-28",{"date":59,"type":32},"2024-05-29",{"date":61,"type":32},"2023-12-18",{"date":63,"type":21},"2024-06-30",{"name":65,"class":39},"Northwestern University",1]